Industry Symposium sponsored by Amicus Therapeutics

Following a path to multisystemic efficacy in Fabry disease

Friday 24 February 2023
06:15–07:15AM ET
Room: Orlando

The journey of a person living with Fabry disease presents many challenges, from diagnosis to treatment, to living with a multisystemic condition. This symposium brings together perspectives from two expert healthcare professionals, Professor Daniel Bichet (Canada) and Professor Derralynn Hughes (UK), to share their insights on the importance of a multisystemic perspective in Fabry disease.

Professor Bichet and Professor Hughes will also discuss long-term safety and multisystemic efficacy of Galafold® (migalastat) in clinical trials and will highlight how this is reflected in their own clinical practice and in real-world data from the followME Fabry Pathfinders registry.

The event will close with an interactive discussion, providing you with a chance to talk to our expert panel about what you heard during the symposium.

Prof Daniel Bichet
Professor and Section Head,
Renal Function and Transport Physiology,
University of Montreal
Quebec, Canada

Professor Derralynn Hughes
Professor Experimental Haematology
Lysosomal Storage Disorders Unit,
Royal Free London NHS Foundation Trust
London, UK

Includes a case study of a person living with Fabry disease

This satellite symposium is organized and funded by Amicus Therapeutics and is open only to healthcare professionals based outside of the US, attending the conference. Amicus' product Galafold® (migalastat) will be discussed at this meeting.

In the UK, migalastat is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation. UK prescribing information is available at this meeting.

Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SmPC). You can also access the UK PI here.

ADVERSE EVENTS SHOULD BE REPORTED

For the UK, reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events in the UK should also be reported to Amicus on **+44 (0) 808 234 6864** or via email to drugsafety@amicusrx.com

For Ireland, adverse events should be reported to the Pharmacovigilance Unit at the Health Products Regulatory Authority (HPRA) at www.hpra.ie. Adverse events in Ireland should also be reported to Amicus on **+353 1800 936 230** or via email to drugsafety@amicusrx.com

This Satellite Symposium is not part of the official WORLD*Symposium*™ program, and WORLD*Symposium* does not approve or endorse any commercial products or services discussed during the Satellite Symposium or offered for sale by the corporate supporter of the Satellite Symposium. This Satellite Symposium is not approved for CME by WORLD*Symposium* or any other entity.

Eligibility: Registration for WORLD*Symposium* 2023 and an official name badge are required to attend this satellite symposium.

Job code: PP-GA-IN-0004-1222 I Date of preparation: December 2022